natgillin/translations-raw huggingface dataset:
136 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
131 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
137 4.5 Interaction with other medicinal products and other forms of interaction
132 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
138 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
133 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
Common: injection site reactions Uncommon: injection site urticaria
Pogosti: reakcije na mestu injiciranja Občasni: urtikarija na mestu injiciranja
139 Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
134 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
140 6.
135 6.
Insulin pen
136 Insulinski injekcijski peresnik
141 The cartridges are to be used in conjunction with an insulin pen such as OptiPen and other pens suitable for Insuman cartridges and as recommended in the information provided by the device manufacturer.
Vložki se uporabljajo skupaj z insulinskim injekcijskim peresnikom kot je OptiPen in drugimi primernimi injekcijskimi peresniki za vložke Insuman in po navodilih izdelovalca injekcijskega peresnika.
Cartridges Before insertion into the pen, Insuman Comb 15 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insuman Comb 15 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insuman Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Comb 15 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
Insuman Comb 15 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Comb 15 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Insuman Comb 15 is a biphasic isophane insulin suspension consisting of 15% dissolved insulin and 85% crystalline protamine insulin.
Insuman Comb 15 je dvofazna suspenzija insulina isofana, sestavljena iz 15% raztopljenega insulina in 85% kristalnega protamin- insulina.
144 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
139 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
145 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
140 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
146 Handling of the pen
Ravnanje z injekcijskim peresnikom
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
141 Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
147 4.8 Undesirable effects
4. 8 Neželeni učinki
Hypoglycaemia, in general the most frequent undesirable effect of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
V kliničnih preskušanjih in med marketinško
In clinical trials and during marketed use, the frequency varies with patient population and dose regimens.
142 uporabo se je pogostnost razlikovala glede na populacijo bolnikov in sheme odmerjanja.
148 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
143 Pogosti: reakcije na mestu injiciranja Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
149 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
144 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
150 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tip 1)) ter prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tip 1)).
Not all pack sizes may be marketed.
145 Na trgu ni vseh navedenih pakiranj.
Insuman Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Comb 15 se ne sme uporabiti, če tega ni mogoče doseči, tj. suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
151 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
146 Ravnanje z injekcijskim peresnikom Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
152 Step 3.
Korak 3.
153 The injection button should be pressed all the way in.
Gumb za injiciranje je treba pritisniti povsem do konca.
155 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
156 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
151 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
157 4.5 Interaction with other medicinal products and other forms of interaction
152 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
158 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
153 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
159 Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
154 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
160 6.
155 6.
The glass cartridge is irreversibly integrated in a transparent container and assembled to a plastic mechanism with a threaded rod at one extremity.
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)). Stekleni vložek je neločljivo vgrajen v prozoren vsebnik; na eni strani ima nameščen plastičen mehanizem z nazobčanim potisnikom.
6.6 Special precautions for disposal and other handling
156 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
161 Insulin pen The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca injekcijskega peresnika.
8.
157 8.
164 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
159 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
165 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
160 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
166 Handling of the pen
161 Ravnanje z injekcijskim peresnikom
167 4.8 Undesirable effects
4. 8 Neželeni učinki
168 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
General disorders and administration site conditions
163 Splošne težave in spremembe na mestu aplikacije
169 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
5.3 Preclinical safety data
164 5. 3 Predklinični podatki o varnosti
170 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Injection needles are not included in the pack.
165 Igle niso priložene.
171 Handling of the pen
166 Ravnanje z injekcijskim peresnikom
172 Step 2.
167 Korak 2.
EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX
168 EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX EU/ 1/ 97/ 030/ XXX
Insuman Comb 25 100 IU/ ml suspension for injection in a vial
Insuman Comb 25 100 i. e. / ml suspenzija za injiciranje v viali
Insuman Comb 25 is a biphasic isophane insulin suspension consisting of 25% dissolved insulin and 75% crystalline protamine insulin.
Insuman Comb 25 je dvofazna suspenzija insulina izofana, sestavljena iz 25% raztopljenega insulina in 75% kristalnega protamin- insulina.
175 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 25 contains 100 IU of insulin per ml suspension.
En mililiter suspenzije Insuman Comb 25 vsebuje 100 i. e. insulina.
Patients hypersensitive to Insuman Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti- allergic treatment.
Bolniki, ki so preobčutljivi za Insuman Comb 25, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
176 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
171 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
177 Intercurrent illness
Sočasne bolezni
Insulin does not cross the placental barrier. Caution should be exercised when prescribing to pregnant women.
Pri predpisovanju zdravila nosečnicam je potrebna previdnost.
Insuman Comb 25 can be used during breastfeeding.
Zdravilo Insuman Comb 25 je med dojenjem dovoljeno uporabljati.
178 4.8 Undesirable effects
4. 8 Neželeni učinki
179 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Insuman Comb 25 (a biphasic isophane insulin suspension with 25% dissolved insulin) is an insulin with gradual onset and long duration of action.
Insuman Comb 25 (dvofazna suspenzija insulina izofana s 25% raztopljenega insulina) je insulin s postopnim začetkom in dolgim trajanjem delovanja.
180 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
181 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
5 ml solution in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
5 ml suspenzija v viali (iz brezbarvnega stekla tipa 1) s prirobljeno zaporko (iz aluminija), z zamaškom (iz klorobutilne gume (tipa 1)) in s pokrovčkom, ki se odtrga (iz polipropilena).
Immediately before withdrawal from the vial into the injection syringe, the insulin must be re-suspended.
176 Tik pred izvlekom iz viale v injekcijsko brizgo je treba insulin ponovno suspendirati.
Insuman Comb 25 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insuman Comb 25 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insuman Comb 25 must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insuman Comb 25 ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
Insuman Comb 25 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insuman Comb 25 se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi- Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insuman Comb 25 must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insuman Comb 25 prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
Insuman Comb 25 40 IU/ ml suspension for injection in a vial
Insuman Comb 25 40 i. e. / ml suspenzija za injiciranje v viali
184 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 25 contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insuman Comb 25 vsebuje 40 i. e. insulina.
185 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
179 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
186 Intercurrent illness
Sočasne bolezni
187 4.8 Undesirable effects
4. 8 Neželeni učinki
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter- regulation.
181 Pri mnogih bolnikih se pred znaki in simptomi nevroglikopenije pojavijo znaki adrenergične protiregulacije.
188 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
182 Večina manjših reakcij na insuline na mestu injiciranja ponavadi mine v nekaj dneh do nekaj tednih.
189 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
190 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Do not shake the vial vigorously as this may lead to changes in the suspension (giving the vial a frosted appearance; see below) and cause frothing.
184 povzroči spremembe v suspenziji (ji da "zamrznjen" videz, glejte spodaj) in povzroči penjenje.
Insuman Comb 25 100 IU/ ml suspension for injection in a cartridge
Insuman Comb 25 100 i. e. / ml suspenzija za injiciranje v vložku
193 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insuman Comb 25 in cartridges has been developed for use in the OptiPen series.
Insuman Comb 25 v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
194 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
187 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
195 4.5 Interaction with other medicinal products and other forms of interaction
188 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
196 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
189 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
197 Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
190 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
198 6.
191 6.
In-use cartridges:
Zdravila Insuman Comb 25 ne shranjujte v bližini zamrzovalnega razdelka ali zamrzovalnega vložka.
199 6.6 Special precautions for disposal and other handling
192 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Cartridges Before insertion into the pen, Insuman Comb 25 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insuman Comb 25 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insuman Comb 25 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insuman Comb 25 se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
200 8.
193 8.
Insuman Comb 25 100 IU/ ml suspension for injection in a pre-filled pen.
Insuman Comb 25 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
En mililiter vsebuje 100 i. e humanega insulina (kar ustreza 3, 5 mg).
202 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
195 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
203 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
196 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
204 Handling of the pen
197 Ravnanje z injekcijskim peresnikom
205 4.8 Undesirable effects
4. 8 Neželeni učinki
206 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
General disorders and administration site conditions
199 Splošne težave in spremembe na mestu aplikacije
207 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
5.3 Preclinical safety data
200 5. 3 Predklinični podatki o varnosti
In-use pens:
Zdravila Insuman Comb 25 ne shranjujte v bližini zamrzovalnega razdelka ali zamrzovalnega vložka.
208 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
Each cartridge contains 3 balls (stainless steel).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1), batom (iz brombutilne gume (tipa 1)) ter prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Injection needles are not included in the pack.
201 V vsakem vložku so 3 kroglice (iz nerjavnega jekla).